The advent of cancer immunotherapy has changed the therapeutic landscape for many hematological cancers—especially for B-cell precursor-ALL (BCP-ALL) as both chimeric antigen receptor T cells (CAR-T) and bispecific T cell engagers (BiTE) targeting CD19 have become commercially available. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.